Johnson & Johnson
J&J MedTech Plans US Clinical Trials for Ottava Surgical Robot in Late 2024
Johnson & Johnson MedTech has set a new timeline for the development of its highly anticipated entry into the competitive ...
Amgen’s Wezlana Emerges as Competitor to J&J’s Stelara, Shaping Medicare Negotiations
Johnson & Johnson may find a silver lining in the recent FDA approval of Amgen’s biosimilar for Stelara. This approval ...
Amgen Secures FDA Approval for Stelara Biosimilar, Awaits 2025 Launch Post-Settlement
The FDA has granted approval to Amgen for its biosimilar rendition of Johnson & Johnson’s renowned autoimmune medication, Stelara. However, ...
AbbVie writes off $2.1B for Imbruvica amid CMS pricing pressure
The introduction of BeiGene’s groundbreaking oral treatment, Brukinsa, has taken a toll on the sales of AbbVie and Johnson & ...
Idorsia slashes 300 jobs in R&D amid cost-cutting efforts
The company has announced that it will be reducing its workforce by 300 individuals, with a focus on R&D and ...
Tremfya clears psoriasis in people of color, first study of its kind shows
The journey to improved treatments for psoriasis, a challenging skin condition, has been long and complex. Despite advances, some patient ...
J&J’s dengue pill shows antiviral activity in human trial, could prevent millions of infections
Amidst Johnson & Johnson’s strategic restructuring in the infectious disease and vaccine divisions, one resilient contender has emerged. JNJ-1802, an ...
Johnson & Johnson Overcomes CAR-T Drug Carvykti’s Launch Challenges with Manufacturing Improvements
Johnson & Johnson (J&J) and Legend Biotech are determined to expand the reach of their CAR-T drug Carvykti for multiple ...
J&J’s drug combo challenges AZ’s Tagrisso in lung cancer, but faces hurdles
In a high-stakes battle, Johnson & Johnson’s drug combination of Rybrevant and the Lazertinib, developed in partnership with Yuhan, has ...
J&J confident in new products as Stelara faces biosimilar threat
In the third quarter of 2023, Johnson & Johnson (J&J) exceeded analyst expectations, solidifying its position as a pharma and ...
AbbVie’s Skyrizi beats J&J’s Stelara in head-to-head Crohn’s disease trial
AbbVie’s Skyrizi has notched a resounding victory over Johnson & Johnson’s biologic drug Stelara in treating Crohn’s disease, as revealed ...
FDA warns J&J’s Abiomed over quality issues with Impella heart pumps and software
The FDA has taken significant steps in its response to safety concerns surrounding certain Abiomed heart pumps. Following several Class ...
Teva and Alvotech face FDA rejection for Stelara biosimilar after Humira setbacks
Ongoing issues at the Alvotech manufacturing facility in Reykjavik have led to yet another FDA rejection, this time affecting the ...
Ablation procedures reduce heart failure risk by 57% in patients with atrial fibrillation, J&J study shows
An extensive retrospective study involving over 18,400 patients with atrial fibrillation (afib) has revealed that individuals who underwent cardiac ablation ...
Johnson & Johnson Secures Talc Victory in New Jersey Court, Erasing $223M Jury Award
Johnson & Johnson, in its latest effort to address the multitude of talc-related lawsuits it faces, suffered a setback when ...
Takeda withdraw Global Lung Cancer Medication, Exkivity, Following Confirmatory Trial Failure
Following a disappointing outcome in a confirmatory trial earlier this year, Takeda has decided to discontinue its targeted non-small cell ...
Sanofi Invests $175M in J&J’s Advanced E. coli Vaccine, Amplifying its Vaccine Development Efforts
Sanofi is making a strategic move by investing $175 million in Johnson & Johnson’s late-phase E. coli vaccine, ExPEC9V. As ...
Johnson & Johnson Offers Global Access by Not Enforcing Sirturo’s Tuberculosis Drug Secondary Patents
Johnson & Johnson has taken significant steps to improve access to its multidrug-resistant tuberculosis (MDR-TB) medication, Sirturo (bedaquiline), in low- ...
J&J teams up with renowned photographer and author to promote eye health awareness
Johnson & Johnson is embarking on a transformative vision campaign, joining forces with renowned New York Times best-selling author, Kate ...
Roivant’s IMVT-1402 lowers IgG without cholesterol or albumin issues, boosting CEO Gline’s debut
Roivant CEO Matt Gline faced an immediate challenge in 2021 when he took the helm, discovering that Immunovant’s lead asset ...
J&J and IBM sued by patients over Janssen CarePath data breach
Johnson & Johnson, already grappling with talc product liability lawsuits, is now facing legal action from patients in relation to ...
Pharma fails to impress mental health patient groups with R&D and pricing practices
The pharmaceutical industry continues to grapple with a less-than-stellar reputation among mental health patient groups, failing to shake off past ...
J&J launches campaign to raise awareness and support for multiple myeloma patients and caregivers
Johnson & Johnson’s multiple myeloma division is embarking on an initiative dubbed “Make It HAPPen,” aimed at bolstering support for ...
Johnson & Johnson and GSK sued for false advertising of decongestant products
A class-action lawsuit has been filed against pharmaceutical giants Johnson & Johnson and Procter & Gamble in a US federal ...
Johnson & Johnson rebrands itself with a new logo and slogan
First Sanofi, GSK, and now Johnson & Johnson are all undergoing significant rebranding efforts in the pharmaceutical industry. In a ...
J&J rebrands Janssen and medtech segments after Kenvue spinoff
Johnson & Johnson (J&J) has undergone a significant corporate transformation, unveiling a new logo and announcing substantial changes to its ...
AbbVie’s Skyrizi beats J&J’s Stelara in Crohn’s disease showdown
AbbVie’s revolutionary anti-inflammatory medication, Skyrizi, has been consistently outperforming its competitors in recent clinical trials, making waves in the field ...
J&J’s Rybrevant Beats Chemo In Lung Cancer Patients Who Failed Tagrisso
The medical community buzzed with anticipation when Johnson & Johnson (J&J) released information about Rybrevant, their latest drug venture into ...
Janssen CarePath Patient Assistance Program Hit By Data Breach, IBM Reports
A technical vulnerability has led to “unauthorized access” to personal data within Johnson & Johnson’s Janssen CarePath patient assistance program, ...
Janssen Drops Cidara’s Flu Medicine After Disappointing Phase 2 Results
Janssen is honoring its 2021 agreement with Cidara Therapeutics regarding the development of CD388, a flu prophylaxis treatment. However, Janssen ...
